According to our examination dental status of long-term survivors is worse than in controls. Hence proper oral hygiene for children cancer survivors (CCS) is critical. In order to meet the need for dental care in CCS health authorities are encouraged to revitalize the dental services Long-term follow-up of CCS is necessary to monitor their dental growth and oral health.

According to these results, chemotherapy in children might result in a decreased stimulated whole saliva flow rate, hyposalivation, and, consequently, increased caries risk. Although these processes might be compensated to a limited extend by the increased minor saliva flow rate, resulting in a higher buffer capacity, nutrition and oral hygiene control of children obtaining cancer therapy is essential in the preservation of the oral tissues.

The availability and adoption of modern therapeutic protocols for childhood cancer have continuously reduced the mortality rate of childhood malignancies in most countries over the past decades. Children being treated for cancer are actively growing, creating unique problems not only in the short-term but also in the long-term development of both the orofacial hard and soft tissue. Complications during and after cancer therapy depend on the type of malignancy, age at diagnosis, and the drugs used during the therapy. The adverse oral effects of irradiation have long been known, and high-dose chemotherapy can cause similar oral late effects, such as dental disturbances, delayed tooth eruption, oral mucosa changes, and craniofacial effects. There are many protocols to prevent acute oral toxicity and infections like mucositis, candidiasis, or hyposalivation. The aim of this chapter is to define the short-term and long-term effects of cancer therapy on the oral health.

Background and objectivePeriodontitis affects up to one billion people worldwide, and has been proven to be associated with several systemic inflammatory conditions. This study investigates the specific relationship between two multifactorial diseases: Inflammatory bowel disease (IBD) and periodontitis. To thoroughly explore this issue, we investigated separately whether IBD patients have a higher chance of developing periodontitis, and equally, whether patients with periodontitis have a higher chance of developing IBD.MethodsThe systematic search was performed in three databases: MEDLINE, Cochrane Trials, and Embase, up to 26 October 2021. The protocol was registered in PROSPERO. All eligible studies investigating the association between IBD and periodontitis from either direction were included. The Newcastle-Ottawa Scale was used to assess the risk of bias. As a primary outcome, we investigated the prevalence of IBD and periodontitis, and calculated the odds ratio (OR). Our secondary outcomes involved comparing the clinical periodontal outcomes of IBD patients to those of IBD-free patients.ResultsThe systematic search resulted in 1,715 records, 14 of which were eligible for qualitative synthesis and 8 for quantitative synthesis. On the basis of the results of the primary outcome, IBD diagnosis was associated with significantly higher odds of periodontitis: OR = 2.65 (CI: 2.09-3.36, I2 = 0 (CI: 0-0.75)). For subgroup analysis, we investigated separately the odds in Crohn’s disease (CD) patients: OR = 2.22 (CI: 1.49-3.31, I2 = 0.05 (CI: 0-0.76)) and in ulcerative colitis (UC) patients: OR = 3.52 (CI: 2.56 to 4.83, I2 = 0 (CI: 0-0.75)); the odds were significantly higher in all cases. Two studies investigated whether patients with periodontitis were more susceptible to IBD, and both found that periodontitis was significantly associated with the risk of subsequent UC, but not with subsequent CD. However, more studies are needed to prove an association.ConclusionOur analysis confirmed that IBD patients have a higher chance of developing periodontitis, and are a higher risk population in dentistry. Both dentists and gastroenterologists should be aware of this relationship and should emphasize the importance of prevention even more than in the healthy population.Systematic review registration[https://www.crd.york.ac.uk/prospero/], identifier [CRD42021286161].

Absztrakt: A WHO által 2020. március 11-én hivatalosan is pandémiának nyilvánított COVID–19-járvány ismét felhívja a figyelmet a telemedicina lehetőségeire. Az új koronavírus-fertőzés megfékezése érdekében, az ellátórendszer működtetése során, a fertőződés kockázatának maximális csökkentése mellett új utakat, módszereket, platformokat kell találnunk. Célunk, hogy szakirodalmi összegzéssel és gyakorlati szempontú útmutatók révén, valamint a hazai telefogászat különleges példáján keresztül bemutassuk, milyen kísérletek történtek a COVID–19-járvány kapcsán a telemedicinának az ellátásba való bevonására mind a nemzetközi, mind pedig a hazai ellátórendszerek különböző szintjein. Mind a nemzetközi, mind a hazai adatok azt mutatják, hogy a telemedicina kiemelt szerepű lehet a triázs folyamatában, a fertőzöttek korai kiemelésében, diagnosztizálásában, ellátásában, betegútjának menedzselésében úgy, hogy a szakszemélyzet nem érintkezik a potenciálisan fertőzött páciensekkel. Ugyancsak fontos szerepe van a gondozott, krónikus betegséggel élő páciensek állapotának távoli monitorozásában, ellátásában és a veszélyeztetett egészségügyi dolgozói csoport ellátásba való visszakapcsolásában. A potenciális előnyök mellett nem szabad megfeledkeznünk a telemedicinális ellátás korlátairól, ugyanakkor fontos kiemelni, hogy széles hozzáférhetősége miatt a veszélyhelyzet kapcsán kellő rugalmasságot adhat mind az alapellátás, mind a szakellátás számára. Éppen ezért mielőbb szükséges a hazai szakmai irányelveket, a jogi és a finanszírozási lehetőségeket e területen hosszú távon fenntartható módon is meghatározni.* Orv Hetil. 2020; 161(24): 983–992. *Megjegyzés: A jelen cikk írását 2020. április 30-án zártuk le. A COVID–19-pandémia és az ezzel kapcsolatos kutatások, vizsgálatok dinamikusan változnak azóta is.